Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Guanfacine extended release - Takeda

Drug Profile

Guanfacine extended release - Takeda

Alternative Names: Connexyn; Intuniv; Intuniv XR; S-877503; SHP 503; SPD-503

Latest Information Update: 12 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire plc
  • Developer Shionogi; Shire; Takeda
  • Class Acetamides; Centrally-acting antihypertensives; Chlorobenzenes; Guanidines; Phenylacetates; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • No development reported Anxiety disorders; Generalised anxiety disorder; Social phobia

Most Recent Events

  • 18 Jun 2019 Launched for Attention-deficit hyperactivity disorder (In adults) in Japan (PO)
  • 13 Jun 2019 Launched for Attention-deficit hyperactivity disorder (Adjunctive treatment, In adolescents, In children) in Australia (PO)
  • 13 Jun 2019 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children) in Norway (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top